溴化异丙托品在慢性阻塞性肺疾病撤机中应用价值探讨

中国临床药理学与治疗学 ›› 2006, Vol. 11 ›› Issue (3): 348-350.

溴化异丙托品在慢性阻塞性肺疾病撤机中应用价值探讨

汪得喜, 潘海燕, 袁建章, 伍惠红, 邓哲彤

广州市红十字会医院,暨南大学医学院第四附属医院呼吸内科,广州 510220,广东

收稿日期:2005-12-20 修回日期:2006-01-25 出版日期:2006-03-26 发布日期:2020-12-04
作者简介:汪得喜,男,医学硕士,副主任医师,主要从事呼吸系统疾病的诊疗及研究工作。Tel:020-34403818 E-mail:wanggorge@126.com

Effect of ipratropium bromide on ventilation weaning in COPD patients

WANG De-xi, PAN Hai-yan, YUAN Jian-zhang, WU Hui-hong, DENG Zhe-tong

Department of Respiration Disease,Guangzhou Red Cross Hospital,the 4th Affiliated Hospital of Medical College of Jinan University,Guangzhou 510220,Guangdong,China

Received:2005-12-20 Revised:2006-01-25 Online:2006-03-26 Published:2020-12-04

摘要/Abstract

摘要： 目的了解增加溴化异丙托品(IB)吸入剂量在撤机困难的中重度慢性阻塞性肺疾病(COPD)病人中的应用价值。方法观察17例在吸入常用剂量(80μg·次^-1)IB的情况下撤机失败的中重度COPD患者撤机期间吸入较大剂量(120μg·次^-1)IB后的情况。结果 17例病人均成功撤机,2、吸入120μgIB后病人脱机时的动脉血气指标优于吸入80μgIB后,病人气促程度(Borg评分)、呼吸频率及心率也低于吸入80μgIB后(P<0.01),且无明显毒副反应出现。结论撤机期内使用较大剂量的IB有助于因气道阻力因素影响撤机的中重度阻塞性肺通气功能障碍的COPD病人撤除呼吸机。

关键词: 慢性阻塞性肺疾病, 溴化异丙托品, M胆碱能受体阻断剂, 机械通气

Abstract: AIM: To study the effect of increasing ipratropium bromide (IB) dosage in the morderated to severe degree COPD patients with difficultly ventilation weaning.METHODS: Observed the effects of high dosage(120μg one time) ipratropium bromide in 17 patients with morderated to severe degree COPD who were fail to ventilation weaning at giving the routine dose (80μg one time) ipratropium bromide.RESULTS: All 17 patients were weaned ventilator successfully.The patients' indexes of artery blood gas analysis with giving high dosage IB were higher than those with routine dosage IB,the patients'modify Borg scores and respiration rates,heart rates with high dosage IB were lower than those with routine dosage IB(P<0.01),no further side effect for increasing IB dosage was observed.CONCLUSION: When the expiratory resistance becomes the most important factor of delaying ventilation weaning,giving a high dosage IB during ventilation weaning period may helPmorderate to severe degree COPD patients weaning the ventilator.

Key words: chronic obstructive pulmonary disease, ipratropium bromide, M anticholinergy receptor, ventilator, ventilation weaning

中图分类号:

R969

汪得喜, 潘海燕, 袁建章, 伍惠红, 邓哲彤. 溴化异丙托品在慢性阻塞性肺疾病撤机中应用价值探讨[J]. 中国临床药理学与治疗学, 2006, 11(3): 348-350.

参考文献

1 Campbell SC.Clinical aspects of inhaled anticholinergic therapy[J].Respir Care,2000;45:864-7
2 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南[J].中华内科杂志,2002;41:640-5
3 唐小葵,王健.机械通气对重症慢性呼吸衰竭患者的疗效分析[J].临床肺科杂志,2001;6:65-6
4 王辰,张洪玉.改进慢性阻塞性肺疾病合并呼吸衰竭的机械通气策略[J].中华内科杂志,2000;39:369-70
5 Borg G.Psychophy sical bases of perceived exertion[J].Med Sci Sports Exert,1982;14:377-81
6 Baxi SC.Kendricj KR,Smith RM.Usefulness of the modified 0-10 Borg scale in assessing the degree of dyspnea in patients with COPD and asthma[J].J Emergency Nursing,2000;26:216-22
7 张爱莉,蔡映云,高育瑶.支气管舒张药雾化吸入治疗研讨会纪要[J].中华结核和呼吸杂志,1998;21:312-3
8 Larsson K.Ipratropium bromide:bronchodilator action and effect on methacholine-induced bronchoconstriction[J].J Asthma,1987;24:29-35
9 Serra C,Giacopelli A,Luciani G.Acute controlled study of the dose-response relationship of fenoterol,ipratropium bromide and their combination[J].Respiration,1986;50:144-710 Gustavo JR,Carlos G.First-Line Therapy for Adult Patients with Acute Asthma Receiving a Multiple-Dose Protocol of Ipratropium Bromide Plus Albuterol in the Emergency Department[J].Am J Respir Crit Care Med,2000;161:1862-8
10 Wolkove N,Dajczman E,Colacone A,Kreisman H.The relationship between pulmonary function and dy spea in obstructive lung disease[J].Chest,1989;96:1247-51
11 Mador MJ,Rodis A,Magalang UJ.Reproducibility of Borg scale measurements of dyspnea during exercise in patients with COPD[J].Chest,1995;107:1590-7
12 Boezen HM,Rijcken B,Schouten JP,Postma DS.Breathlessness in elderly individuals is related to low lung function and reversibility of airway obstruction[J].Eur Respir J,1998;12:805-10

[1]	白学敏，邹立考，金珍木，姜利佳. N-乙酰半胱氨酸通过调控EGFR/MAPK信号通路对慢性阻塞性肺疾病气道黏液高分泌的作用研究[J]. 中国临床药理学与治疗学, 2019, 24(10): 1120-1127.
[2]	贺筱彬，林小华，刘舜莉，欧焕娇. 血嗜酸性粒细胞水平影响慢性阻塞性肺疾病急性加重患者使用全身糖皮质激素的药物利用评价[J]. 中国临床药理学与治疗学, 2019, 24(1): 89-93.
[3]	陆亚君，黄晓颖，傅中明. 铝碳酸镁联合PPI治疗COPD合并咽喉反流的疗效及对AECOPD的预防作用[J]. 中国临床药理学与治疗学, 2018, 23(11): 1270-1275.
[4]	刘晓萍，赖香茂，王海全，陈玉梅，张冬梅. 药物整合在慢性阻塞性肺疾病合并焦虑抑郁障碍患者中的应用价值[J]. 中国临床药理学与治疗学, 2016, 21(9): 1038-1041.
[5]	韦柳萍，宋林，杨彬. 联合吸入噻托溴铵与糖皮质激素/长效β₂受体激动剂治疗稳定期慢性阻塞性肺疾病有效性和安全性的系统评价[J]. 中国临床药理学与治疗学, 2016, 21(7): 777-783.
[6]	王月花，宋昱晨，赵美芳，沈香娣. 福多司坦治疗慢性阻塞性肺疾病稳定期的随机对照双盲试验[J]. 中国临床药理学与治疗学, 2015, 20(11): 1283-1286.
[7]	黄友明, 王安才, 查日田. 舒利迭联合茶碱对慢性阻塞性肺疾病稳定期患者肺动脉压及右心功能的观察[J]. 中国临床药理学与治疗学, 2014, 19(8): 920-925.
[8]	俞万钧, 王华英, 翁跃颂, 宋嫣瑾, 顾霄, 应华娟. 短期与长期烟草烟雾暴露小鼠中CD₄^＋Foxp3^＋调节性T细胞的变化及意义[J]. 中国临床药理学与治疗学, 2014, 19(6): 601-606.
[9]	汪辰吟, 陶秀华, 张弦, 汪电雷, 陈金佩, 杨丽丽, 曹银, 汪珊珊. 慢性阻塞性肺疾病进程与肺支气管上皮细胞MRP1功能改变的相关性研究[J]. 中国临床药理学与治疗学, 2014, 19(1): 8-14.
[10]	骆松梅, 叶伟红, 华俊彦. 临床药师参与慢性阻塞性肺病急性加重期患者治疗的实践[J]. 中国临床药理学与治疗学, 2013, 18(9): 1014-1018.
[11]	钱小英, 吴厉锋, 徐滨. 阿奇霉素对慢性阻塞性肺疾病急性加重患者的免疫调节作用研究[J]. 中国临床药理学与治疗学, 2013, 18(11): 1288-1290.
[12]	赵恬, 顾亮, 杜坚宗, 钦光跃. 孟鲁司特治疗老年稳定期慢性阻塞性肺疾病患者的疗效分析[J]. 中国临床药理学与治疗学, 2013, 18(1): 66-70.
[13]	周颖, 金前, 柴秀娟. 福多司坦治疗慢性阻塞性肺疾病急性加重患者的临床观察[J]. 中国临床药理学与治疗学, 2012, 17(3): 334-337.
[14]	童亚玲, 李乾兵, 徐建林, 陈俊. 沙美特罗替卡松(舒利迭)联合双水平气道正压通气对中重度COPD合并Ⅱ型呼吸衰竭患者生活质量的影响[J]. 中国临床药理学与治疗学, 2012, 17(12): 1392-1397.
[15]	何剑波, 颜孙舜, 徐慧, 戴元荣, 吴成云, 翁海霞, 吴立琴. 氧驱动雾化吸入布地奈德混悬液和复方异丙托溴铵溶液对慢性阻塞性肺疾病急性加重期Ⅱ型呼吸衰竭患者的影响[J]. 中国临床药理学与治疗学, 2009, 14(2): 199-202.